| scholarly article | Q13442814 |
| P50 | author | Mary A. Whooley | Q56332432 |
| Joachim H. Ix | Q87220141 | ||
| Michael G Shlipak | Q87224063 | ||
| Glenn Chertow | Q87653339 | ||
| P2860 | cites work | Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study | Q24654287 |
| Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients | Q28193844 | ||
| Cystatin C and the risk of death and cardiovascular events among elderly persons | Q28251528 | ||
| Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement | Q28256758 | ||
| Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 | ||
| Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome | Q28287352 | ||
| Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate | Q28295117 | ||
| Evaluation of methods for the measurement of low-density lipoprotein cholesterol. | Q29547378 | ||
| K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification | Q29547560 | ||
| C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study | Q30763122 | ||
| Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study | Q31035233 | ||
| Serum cystatin C concentration as a marker of renal dysfunction in the elderly | Q31794722 | ||
| Serum cystatin C as an endogenous marker of the renal function--a review | Q33658748 | ||
| Gender and the progression of renal disease | Q34165566 | ||
| Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease | Q34378516 | ||
| Leptin and renal disease | Q34482861 | ||
| Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic | Q35040738 | ||
| Microalbuminuria: definition, detection, and clinical significance | Q35945733 | ||
| Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study | Q37405433 | ||
| Depressive symptoms and health-related quality of life: the Heart and Soul Study | Q37419710 | ||
| Measurement of renal function in chronic renal disease | Q37947109 | ||
| Clinical evaluation of kidney function--glomerular function | Q39999345 | ||
| Cystatin C and mortality risk in the elderly: the health, aging, and body composition study | Q40375333 | ||
| Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease | Q43723152 | ||
| Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). | Q43964542 | ||
| Cystatin C concentration as a risk factor for heart failure in older adults | Q46421474 | ||
| Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). | Q46466510 | ||
| Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women | Q46580577 | ||
| Kidney function as a predictor of noncardiovascular mortality | Q46776022 | ||
| Cystatin C--a new marker of glomerular filtration rate in children independent of age and height | Q47288949 | ||
| Biological variation of cystatin C: implications for the assessment of glomerular filtration rate | Q47840399 | ||
| Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. | Q51679983 | ||
| Case Definitions for Acute Coronary Heart Disease in Epidemiology and Clinical Research Studies | Q57154327 | ||
| Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine | Q72192988 | ||
| Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment | Q73938868 | ||
| Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System | Q77333340 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| heart failure | Q181754 | ||
| heart disease | Q190805 | ||
| coronary artery disease | Q844935 | ||
| P304 | page(s) | 173-9 | |
| P577 | publication date | 2007-01-16 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study | |
| P478 | volume | 115 |
| Q35098249 | A biomarker panel for peripheral arterial disease |
| Q33691644 | Application of cystatin C reduction ratio to high-flux hemodialysis as an alternative indicator of the clearance of middle molecules. |
| Q57070928 | Association Between Increased Levels of Cystatin C and the Development of Cardiovascular Events or Mortality: A Systematic Review and Meta-Analysis |
| Q35250898 | Association between Cystatin C and MRI Measures of Left Ventricular Structure and Function: Multi-Ethnic Study of Atherosclerosis |
| Q58562028 | Association between Serum Cystatin C and Vascular Complications in Type 2 Diabetes Mellitus without Nephropathy |
| Q42920664 | Association between cystatin C and inflammation in patients with essential hypertension |
| Q36555620 | Association between kidney function and telomere length: the heart and soul study |
| Q44212877 | Association between serum cystatin C levels and coronary slow flow |
| Q33276760 | Association of cystatin C with poor exercise capacity and heart rate recovery: data from the heart and soul study |
| Q36667225 | Association of mild to moderate kidney dysfunction and coronary calcification |
| Q64898031 | Association of serum cystatin C levels with acute coronary syndrome in patients of advanced age. |
| Q33617174 | Association of serum phosphorus with left ventricular mass in men and women with stable cardiovascular disease: data from the Heart and Soul Study |
| Q38978842 | Associations of Conventional Echocardiographic Measures with Incident Heart Failure and Mortality: The Chronic Renal Insufficiency Cohort |
| Q34150807 | Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study |
| Q38079565 | Biomarkers in atrial fibrillation: a clinical review |
| Q37893446 | Biomarkers in chronic kidney disease: a review |
| Q37339808 | Biomarkers in heart failure: a clinical review. |
| Q37307999 | Biomarkers of atherosclerosis: clinical applications |
| Q36455014 | Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study |
| Q37095187 | Cardiorenal syndrome type 4: a review |
| Q35176802 | Chronic kidney disease and end-stage renal disease in the elderly population: current prevalence, future projections, and clinical significance |
| Q46249681 | Circadian variability of cystatin C, creatinine, and glomerular filtration rate (GFR) in healthy men during normal sleep and after an acute shift of sleep |
| Q46312965 | Clinical utility of serum cystatin C in predicting coronary artery disease in patients without chronic kidney disease. |
| Q38042554 | Comparing new onset heart failure with reduced ejection fraction and new onset heart failure with preserved ejection fraction: an epidemiologic perspective |
| Q30375808 | Conformational transitions induced by in vitro macromolecular crowding lead to the amyloidogenesis of buffalo heart cystatin. |
| Q39447438 | Contribution of cystatin C gene polymorphisms to cerebral white matter lesions |
| Q36265357 | Correlations of serum cystatin C and glomerular filtration rate with vascular lesions and severity in acute coronary syndrome |
| Q35658295 | Cystatin C Is Not Causally Related to Coronary Artery Disease |
| Q30276065 | Cystatin C and Cardiovascular Disease: A Mendelian Randomization Study |
| Q36027716 | Cystatin C and Risk of Diabetes and the Metabolic Syndrome - Biomarker and Genotype Association Analyses |
| Q43180532 | Cystatin C and cardiac hypertrophy in primary hypertension. |
| Q46157359 | Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study |
| Q43119836 | Cystatin C and cardiovascular risk in the general population |
| Q34614924 | Cystatin C and carotid intima-media thickness in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). |
| Q24685074 | Cystatin C and risk of heart failure in the Physicians' Health Study (PHS) |
| Q58121766 | Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome |
| Q54531871 | Cystatin C identifies cardiovascular risk better than creatinine-based estimates of glomerular filtration in middle-aged individuals without a history of cardiovascular disease. |
| Q36345739 | Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events |
| Q37155015 | Cystatin C in Acute Coronary Syndrome |
| Q36103793 | Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study |
| Q85523104 | Cystatin C in children on chronic hemodialysis |
| Q51474303 | Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth. |
| Q36094689 | Cystatin C is associated with risk of venous thromboembolism in subjects with normal kidney function--the Tromsø study |
| Q89347261 | Cystatin C may not be a precious predictor for coronary artery disease and its severity: an area of uncertainty |
| Q46030370 | Cystatin C provides more information than other renal function parameters for stratifying risk in patients with acute coronary syndrome. |
| Q42258841 | Cystatin C reduction ratio depends on normalized blood liters processed and fluid removal during hemodialysis |
| Q33830165 | Cystatin C, a novel indicator of renal function, reflects severity of cerebral microbleeds |
| Q42803609 | Cystatin C, creatinine, and albuminuria: bringing risk into 3 dimensions |
| Q49041943 | Cystatin C, creatinine, estimated glomerular filtration, and long-term mortality in stroke patients |
| Q37301522 | Cystatin C, other markers of kidney disease, and incidence of age-related cataract |
| Q35511202 | Cystatin C, renal function, and atherosclerosis in rheumatoid arthritis |
| Q36869663 | Cystatin C--a paradigm of evidence based laboratory medicine. |
| Q41636688 | Cystatin C-Adiponectin Complex in Plasma Associates with Coronary Plaque Instability |
| Q51102049 | Cystatin C: a potential biomarker for pulmonary arterial hypertension. |
| Q37856794 | Cystatin C: a step forward in assessing kidney function and cardiovascular risk |
| Q28534470 | Cystatin C: a strong marker for lower limb ischemia in Chinese type 2 diabetic patients? |
| Q50222299 | Cystatin-C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly |
| Q35832990 | Diagnostic value of cystatin C for predicting acute kidney injury in patients with liver cirrhosis |
| Q33849516 | Dietary protein intake and change in estimated GFR in the Cardiovascular Health Study |
| Q33654021 | Diminished Renal Function and the Incidence of Heart Failure |
| Q43109634 | Discrepancies between creatinine- and cystatin C-based equations: implications for identification of chronic kidney disease in the general population |
| Q43534627 | Elevated serum cystatin C in severe OSA younger men without complications |
| Q34870809 | Estimated GFR associates with cardiovascular risk factors independently of measured GFR. |
| Q28084462 | Evaluation of chronic kidney disease in chronic heart failure: From biomarkers to arterial renal resistances |
| Q34627702 | Exercise electrocardiographic responses and serum cystatin C levels among metabolic syndrome patients without overt diabetes mellitus |
| Q97555768 | Extracellular vesicle Cystatin C and CD14 are associated with both renal dysfunction and heart failure |
| Q36095111 | Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). |
| Q33988990 | Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study |
| Q40243049 | Global Cardiovascular and Renal Outcomes of Reduced GFR. |
| Q37626254 | Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals |
| Q22306356 | Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association |
| Q22241921 | Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association |
| Q30238784 | Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association |
| Q47437642 | Heart Failure and Kidney Disease. |
| Q29547236 | Heart disease and stroke statistics--2011 update: a report from the American Heart Association |
| Q29547909 | Heart disease and stroke statistics--2012 update: a report from the American Heart Association |
| Q29547691 | Heart disease and stroke statistics--2014 update: a report from the American Heart Association |
| Q36635034 | Higher Levels of Cystatin C Are Associated with Extracranial Carotid Artery Steno-Occlusive Disease in Patients with Noncardioembolic Ischemic Stroke |
| Q35032801 | Higher cystatin C level predicts long-term mortality in patients with peripheral arterial disease. |
| Q57448723 | Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty |
| Q36207827 | Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C |
| Q35020305 | Improving prognosis estimation in patients with heart failure and the cardiorenal syndrome |
| Q41088013 | Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents |
| Q46923821 | Increased myocardial ischemia-reperfusion injury in renal failure involves cardiac adiponectin signal deficiency |
| Q28244928 | Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: the Dallas Heart Study |
| Q42587254 | Is Cystatin C an Important Prognostic Marker Independent of Renal Function? |
| Q37245464 | Kidney function and estimated vascular risk in patients with primary dyslipidemia |
| Q37518114 | Kidney function and mortality in octogenarians: Cardiovascular Health Study All Stars |
| Q33904523 | Lack of Association between Serum Cystatin C Levels and Coronary Artery Disease in Diabetic Patients |
| Q34512274 | Limited value of cystatin-C over estimated glomerular filtration rate for heart failure risk stratification. |
| Q35562745 | Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers |
| Q38704885 | Mendelian Randomization for the Identification of Causal Pathways in Atherosclerotic Vascular Disease |
| Q37890908 | Novel biomarkers in acute heart failure |
| Q37997237 | Novel biomarkers in chronic heart failure |
| Q38864815 | Novel biomarkers with potential for cardiovascular risk reclassification |
| Q38882637 | OLDER PEOPLE WITH CHRONIC KIDNEY DISEASE: DEFINITION, AND INFLUENCE OF BIOMARKERS AND MEDICATIONS UPON CARDIOVASCULAR AND RENAL OUTCOMES. |
| Q36863889 | Overlap between common genetic polymorphisms underpinning kidney traits and cardiovascular disease phenotypes: the CKDGen consortium |
| Q35858646 | Plasma Levels of Middle Molecules to Estimate Residual Kidney Function in Haemodialysis without Urine Collection |
| Q48023391 | Potential contribution of adipose tissue to elevated serum cystatin C in human obesity |
| Q33591588 | Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC). |
| Q34021375 | Prevalence of kidney disease in anaemia differs by GFR-estimating method: the Third National Health and Nutrition Examination Survey (1988-94). |
| Q37878492 | Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target |
| Q35133148 | Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis |
| Q33646576 | Rate of kidney function decline in older adults: a comparison using creatinine and cystatin C. |
| Q35421211 | Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study |
| Q85614047 | Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy |
| Q37615466 | Relationship between serum cystatin C and polycystic ovary syndrome |
| Q82732442 | Relationship between serum cystatin C and serum adiponectin level in type 2 diabetic patients |
| Q37416394 | Relationship of urine dopamine with phosphorus homeostasis in humans: the heart and soul study |
| Q90148126 | Relative value of cystatin C and creatinine-based estimates of glomerular filtration rate in predicting long-term mortality after cardiac surgery: a cohort study |
| Q51181204 | Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. |
| Q38177341 | Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers |
| Q58121740 | Role for Cystatin C-Based Risk Stratification for Patients After Acute Coronary Syndrome in the Era of High Sensitivity Cardiac Troponin Assays |
| Q40998882 | Serum Cystatin C and the Risk of Coronary Heart Disease in Ethnic Chinese Patients With Normal Renal Function |
| Q36001110 | Serum Cystatin C as an Indicator of Renal Function and Mortality in Liver Transplant Recipients |
| Q37179085 | Serum cystatin C and the risk of Alzheimer disease in elderly men |
| Q37229937 | Serum cystatin C concentration as an independent marker for hypertensive left ventricular hypertrophy |
| Q53704024 | Serum cystatin C is an independent biomarker associated with the renal resistive index in patients with chronic kidney disease. |
| Q47638003 | Serum cystatin C is associated with kidney function but not with cardiovascular risk factors or subclinical atherosclerosis in patients with Systemic Lupus Erythematosus |
| Q36392738 | Serum cystatin C- versus creatinine-based definitions of acute kidney injury following cardiac surgery: a prospective cohort study |
| Q36328272 | Soluble endothelial cell selective adhesion molecule and cardiovascular outcomes in patients with stable coronary disease: A report from the Heart and Soul Study |
| Q51628025 | Subclinical Organ Damage in White-Coat Hypertension: The Possible Role of Cystatin C. |
| Q35160307 | The association of chronic kidney disease and metabolic syndrome with incident cardiovascular events: multiethnic study of atherosclerosis |
| Q35557044 | The effect of including cystatin C or creatinine in a cardiovascular risk model for asymptomatic individuals: the multi-ethnic study of atherosclerosis |
| Q42772483 | The relationship of cystatin C, creatinine, estimated GFR, and cardiovascular events |
| Q38104269 | The use of biomarkers in the patient with heart failure |
| Q30793329 | Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study |
| Q79882279 | [Biomarkers in cardiology--state of the art 2007] |
Search more.